Skip to main content
. 2015 Sep;59:59–70. doi: 10.1016/j.psyneuen.2015.05.003

Figure 1.

Figure 1

(A) Feto-placental 11β-HSD2 activity at E12.5. 11β-HSD2 activity is reduced in the fetal head of E12.5 HSD2BKO mice (n = 6) in comparison to controls (n = 6). Within the placenta and the remainder of the fetal body 11β-HSD2 activity was unaltered by phenotype (n = 5–7). **p < 0.005 compared to controls. (B) Hsd11b2 mRNA levels in fetal brain. Hsd11b2 mRNA levels are reduced dramatically at E12.5 in HSD2BKO (n = 5) compared to controls (n = 5) while minimal expression is seen in either genotype at E17.5 (n = 4–5). 2-Way ANOVA reveals significant effects of genotype (F(1,15) = 9.697, p = 0.007), age (F(1,15) = 9.519, p = 0.0075) and interaction (F(1,15) = 9.498, p = 0.0076). (C) Brain corticosterone content at E15.5 and E17.5. Corticosterone content is increased in brain of E15.5 HSD2BKO (n = 10) compared to controls (n = 9). *p < 0.05 compared to Controls.

HHS Vulnerability Disclosure